Antifungal therapy of Candida biofilms: past, present and future

Olabayo H. Ajetunmobi; Hamid Badali; Jesus A. Romo; Gordon Ramage; Jose L. Lopez-Ribot

doi:10.1016/j.bioflm.2023.100126

Antifungal therapy of Candida biofilms: past, present and future

Olabayo H. Ajetunmobi, Hamid Badali, Jesus A. Romo, Gordon Ramage, Jose L. Lopez-Ribot^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

34 Downloads (Pure)

Abstract

Virtually all Candida species linked to clinical candidiasis are capable of forming highly resistant biofilms on different types of surfaces, which poses an additional significant threat and further complicates therapy of these infections. There is a scarcity of antifungal agents, and their effectiveness, particularly against biofilms, is limited. Here we provide a historical perspective on antifungal agents and therapy of Candida biofilms. As we reflect upon the past, consider the present, and look towards the future of antifungal therapy of Candida biofilms, we believe that there are reasons to remain optimistic, and that the major challenges of Candida biofilm therapy can be conquered within a reasonable timeframe.

Original language	English
Article number	100126
Number of pages	8
Journal	Biofilm
Volume	5
Early online date	23 Apr 2023
DOIs	https://doi.org/10.1016/j.bioflm.2023.100126
Publication status	Published - Dec 2023
Externally published	Yes

Keywords

Antifungal agents
Biofilm
Candida spp.

ASJC Scopus subject areas

Microbiology
Applied Microbiology and Biotechnology
Molecular Biology
Cell Biology

Documents and Links

10.1016/j.bioflm.2023.100126

Final published versionFinal published version, 547 KBLicence: CC BY-NC-ND

Cite this

@article{59ca1d4b5c7a4376b391e2c63ce45deb,

title = "Antifungal therapy of Candida biofilms: past, present and future",

abstract = "Virtually all Candida species linked to clinical candidiasis are capable of forming highly resistant biofilms on different types of surfaces, which poses an additional significant threat and further complicates therapy of these infections. There is a scarcity of antifungal agents, and their effectiveness, particularly against biofilms, is limited. Here we provide a historical perspective on antifungal agents and therapy of Candida biofilms. As we reflect upon the past, consider the present, and look towards the future of antifungal therapy of Candida biofilms, we believe that there are reasons to remain optimistic, and that the major challenges of Candida biofilm therapy can be conquered within a reasonable timeframe.",

keywords = "Antifungal agents, Biofilm, Candida spp.",

author = "Ajetunmobi, {Olabayo H.} and Hamid Badali and Romo, {Jesus A.} and Gordon Ramage and Lopez-Ribot, {Jose L.}",

note = "Funding Information: Biofilm work in the JL-R laboratory is supported by NIH grants R33AI140823 and R21AI156100 from the National Institute of Allergy and Infectious Diseases . Additional support was provided by the Margaret Batts Tobin Foundation , San Antonio, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the content is solely the responsibility of the authors.",

year = "2023",

month = dec,

doi = "10.1016/j.bioflm.2023.100126",

language = "English",

volume = "5",

journal = "Biofilm",

issn = "2590-2075",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Antifungal therapy of Candida biofilms: past, present and future

AU - Ajetunmobi, Olabayo H.

AU - Badali, Hamid

AU - Romo, Jesus A.

AU - Ramage, Gordon

AU - Lopez-Ribot, Jose L.

N1 - Funding Information: Biofilm work in the JL-R laboratory is supported by NIH grants R33AI140823 and R21AI156100 from the National Institute of Allergy and Infectious Diseases . Additional support was provided by the Margaret Batts Tobin Foundation , San Antonio, TX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the content is solely the responsibility of the authors.

PY - 2023/12

Y1 - 2023/12

N2 - Virtually all Candida species linked to clinical candidiasis are capable of forming highly resistant biofilms on different types of surfaces, which poses an additional significant threat and further complicates therapy of these infections. There is a scarcity of antifungal agents, and their effectiveness, particularly against biofilms, is limited. Here we provide a historical perspective on antifungal agents and therapy of Candida biofilms. As we reflect upon the past, consider the present, and look towards the future of antifungal therapy of Candida biofilms, we believe that there are reasons to remain optimistic, and that the major challenges of Candida biofilm therapy can be conquered within a reasonable timeframe.

AB - Virtually all Candida species linked to clinical candidiasis are capable of forming highly resistant biofilms on different types of surfaces, which poses an additional significant threat and further complicates therapy of these infections. There is a scarcity of antifungal agents, and their effectiveness, particularly against biofilms, is limited. Here we provide a historical perspective on antifungal agents and therapy of Candida biofilms. As we reflect upon the past, consider the present, and look towards the future of antifungal therapy of Candida biofilms, we believe that there are reasons to remain optimistic, and that the major challenges of Candida biofilm therapy can be conquered within a reasonable timeframe.

KW - Antifungal agents

KW - Biofilm

KW - Candida spp.

U2 - 10.1016/j.bioflm.2023.100126

DO - 10.1016/j.bioflm.2023.100126

M3 - Article

AN - SCOPUS:85153258632

SN - 2590-2075

VL - 5

JO - Biofilm

JF - Biofilm

M1 - 100126

ER -

Antifungal therapy of Candida biofilms: past, present and future

Abstract

Keywords

ASJC Scopus subject areas

Documents and Links

Fingerprint

Cite this